

Enrolled 183% of the Expected Goal with 0% Discontinuation in Top 5 Site Performance

Our Objectives

DelRicht Research was selected as a participating site network for a Phase 2 clinical trial targeting adults with obesity. The trial aimed to recruit a broad adult population aged 18–75.

- **Total Enrollment Goal:** 360 participants across 60 sites
- **DelRicht's Enrollment Goal:** 6 participants at 1 site
- **Patient Population:** Participants 18–75 years of age
- **Enrollment Period:** March 2025 – June 2025

Trial Challenges

The protocol required patients to complete a successful ABPM reading prior to randomization, but device access was limited to five units. This constraint introduced scheduling complexity and potential risk of delays. Additionally, eligibility criteria regarding depression history required close review of patients in screening. This detail introduced a layer of complexity to enrollment planning and patient eligibility review.

Our Results

Despite strict pre-randomization requirements and eligibility criteria, DelRicht achieved successful enrollment by **1) coordinating ABPM scheduling to ensure efficient device turnaround resulting in no missed baselines, and 2) collaborating closely with the study CRA** to navigate eligibility criteria, proactively review affected patients, and maintain enrollment momentum.

DelRicht's site in Tulsa, OK successfully **enrolled 11 participants, 183% of the expected goal, with a 0% discontinuation rate.** Recognized as **one of the top 5 enrolling sites in the study**, this performance highlights the strength of our operations and patient-focused approach. Across therapeutic areas, DelRicht continues to deliver through community engagement and operational excellence.

The Study

Client: Large Pharma

Trial: Global Phase 2
Obesity Trial

Patient Population: Adults 18–75 years of age with obesity

Participating PI



Dr. Melita Tate

Tulsa, OK
Grassroots
Healthcare

